Key result
Schizophrenia was associated with a significantly higher 10-year cardiovascular risk (5.16%) compared to healthy controls (3.02%, p=0.030), which correlated with disease duration and hospitalizations.
Why the study?
Patients with schizophrenia have increased cardiovascular disease risk compared to the general population, but the relationship between heart disease risk and schizophrenia symptomatology remains to be clarified.
Does schizophrenia and its symptomatology increase the 10-year risk of cardiovascular disease compared to healthy controls?
Cross-Sectional (n=142)
No
Does schizophrenia and its symptomatology increase the 10-year risk of cardiovascular disease compared to healthy controls?
Schizophrenia is associated with an increased 10-year cardiovascular risk that correlates with disease duration, number of hospitalizations, and antipsychotic polypharmacy, rather than specific psychiatric symptoms.
Schizophrenia symptom severity may correlate with 10-year CVD risk; leaves open independent contribution beyond known factors.
OBJECTIVE: Previous research shows that patients with schizophrenia have increased cardiovascular disease risk than general population. Increased cardiovascular risk in schizophrenia patients have been associated with many reasons such as antipsychotic drugs, genetic predisposition, andlifestyle. In this study, we aimed to investigate the relationship between the risk of heart disease and schizophrenia symptomatology. METHODS: The 10-year cardiovascular risk was assessed by the Framingham Risk Score (FRS) in 103 patients with schizophrenia and in 39 healthy controls. Sociodemographic characteristics, age at schizophrenia onset, duration of illness, number of hospitalizations, the course of the disease and antipsychotic medications were recorded. Patients' symptoms were evaluated via The Scale for the Assessment of Negative Symptoms (SANS), The Scale for the Assessment of Positive Symptoms (SAPS), and Calgary Depression Scale for Schizophrenia (CDSS). RESULTS: Ten-year cardiovascular risk was 5.16% inpatients with schizophrenia, and 3.02% in control group (p=0.030). No significant correlation was found between FRS scores, SANS, SAPS, and CDSS scores. However, FRS scores were significantly correlated with age, number of hospitalizations and duration of disease (r=0.300, 0.261, 0.252, respectively). Moreover FRS scores were higher (p=0.008) and high-density lipoprotein (HDL) levels were lower (p=0.048) in patients using multiple antipsychotics. CONCLUSION: Our findings suggest a relationship between the risk of cardiovascular disease and the duration and overall severity of schizophrenia and also highlights the role of antipsychotics in this relationship.
No takes yet. Share an insight, caveat, or question.
Kılıçaslan et al. (2019) conducted a cross-sectional in Schizophrenia (n=142). Schizophrenia vs. Healthy controls was evaluated on 10-year cardiovascular risk (Framingham Risk Score) (p=0.030). Schizophrenia was associated with a significantly higher 10-year cardiovascular risk (5.16%) compared to healthy controls (3.02%, p=0.030), which correlated with disease duration and hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: